Endoluminal radiofrequency ablation of hilarcholangiocarcinoma

a 2016

Endoluminal radiofrequency ablation of hilarcholangiocarcinoma

ANDRAŠINA, Tomáš; Jiří PÁNEK; Jan HLAVSA; Vladan BERNARD; Vlastimil VÁLEK et al.

Základní údaje

Originální název

Endoluminal radiofrequency ablation of hilarcholangiocarcinoma

Autoři

ANDRAŠINA, Tomáš; Jiří PÁNEK; Jan HLAVSA; Vladan BERNARD a Vlastimil VÁLEK

Vydání

ESGAR 2016, 2016

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30224 Radiology, nuclear medicine and medical imaging

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

ESGAR Book of abstracts 2016

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00088926

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s13244-016-0502-9

Klíčová slova česky

radiofrekvenční ablace; rakovina žlučových cest; perkutánní drenáže

Klíčová slova anglicky

radiofrequency ablation; biliary cancer; percutaneous drainage

Změněno: 26. 1. 2019 21:05, MUDr. Tomáš Andrašina, Ph.D.

Anotace

V originále

Purpose: To prove efficacy of endoluminal radiofrequency ablation in palliative treatment of hilar cholangiocarcinoma. Material and methods: 35 patients with hilar cholangiocarcinoma have been enrolled in a prospective randomised study since 2010. The infiltrative type of cholangiocarcinoma was predominant. 65 non-covered self-expandable metal stents were inserted. In group A (n=18) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB; EMcision Ltd., London, UK) was performed 0-48 hours prior to the stent insertion, in group B (n=17) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meier analysis). Results: The rate of biochemical pancreatitis, which was resolved in 3 days after stent insertion, was significantly higher in group A. The average primary stent patency was 5.9 and 5.7 months in groups A and B, respectively; 3-month and 6-month stent failure was 0% and 6.1% in group A and 6.3% and 25% in group B. The median survival from the initial drainage was 12.3 (6.7- 20.1) and 12.8 (5.7-14.7) months in groups A and B, respectively. Conclusion: The effect of an endoluminal ablation on patients survival was not proven in the prospective randomised clinical study. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. The intervention should be associated with very mild biochemical pancreatitis.

Návaznosti

MUNI/A/1083/2015, interní kód MU

Název: Radiologické diagnostické a intervenční postupy u onkologických pacientů a jejich přínos v rámci komplexní onkologické léčby s důrazem na farmakoekonomické aspekty.

Investor: Masarykova univerzita, Radiologické diagnostické a intervenční postupy u onkologických pacientů a jejich přínos v rámci komplexní onkologické léčby s důrazem na farmakoekonomické aspekty., DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

NV15-32484A, projekt VaV

Název: Využití nových biotechnologií v prevenci a léčbě stenóz žlučových cest

Citovat

ANDRAŠINA, Tomáš; Jiří PÁNEK; Jan HLAVSA; Vladan BERNARD a Vlastimil VÁLEK. Endoluminal radiofrequency ablation of hilarcholangiocarcinoma. In ESGAR 2016. 2016. Dostupné z: https://doi.org/10.1007/s13244-016-0502-9.

@proceedings{1364968,
   author = {Andrašina, Tomáš and Pánek, Jiří and Hlavsa, Jan and Bernard, Vladan and Válek, Vlastimil},
   booktitle = {ESGAR 2016},
   doi = {https://doi.org/10.1007/s13244-016-0502-9},
   keywords = {radiofrequency ablation; biliary cancer; percutaneous drainage},
   language = {eng},
   title = {Endoluminal radiofrequency ablation of hilarcholangiocarcinoma},
   url = {http://paperity.org/p/76277811/esgar-2016-book-of-abstracts},
   year = {2016}
}

TY  - CONF
ID  - 1364968
AU  - Andrašina, Tomáš - Pánek, Jiří - Hlavsa, Jan - Bernard, Vladan - Válek, Vlastimil
PY  - 2016
TI  - Endoluminal radiofrequency ablation of hilarcholangiocarcinoma
KW  - radiofrequency ablation
KW  - biliary cancer
KW  - percutaneous drainage
UR  - http://paperity.org/p/76277811/esgar-2016-book-of-abstracts
L2  - http://paperity.org/p/76277811/esgar-2016-book-of-abstracts
N2  - Purpose: To prove efficacy of endoluminal radiofrequency ablation in palliative treatment of hilar cholangiocarcinoma. Material and methods: 35 patients with hilar cholangiocarcinoma have been enrolled in a prospective randomised study since 2010. The infiltrative type of cholangiocarcinoma was predominant. 65 non-covered self-expandable metal stents were inserted. In group A (n=18) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB; EMcision Ltd., London, UK) was performed 0-48 hours prior to the stent insertion, in group B (n=17) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meier analysis). Results: The rate of biochemical pancreatitis, which was resolved in 3 days after stent insertion, was significantly higher in group A. The average primary stent patency was 5.9 and 5.7 months in groups A and B, respectively; 3-month and 6-month stent failure was 0% and 6.1% in group A and 6.3% and 25% in group B. The median survival from the initial drainage was 12.3 (6.7- 20.1) and 12.8 (5.7-14.7) months in groups A and B, respectively. Conclusion: The effect of an endoluminal ablation on patients survival was not proven in the prospective randomised clinical study. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. The intervention should be associated with very mild biochemical pancreatitis.
ER  -

ANDRAŠINA, Tomáš; Jiří PÁNEK; Jan HLAVSA; Vladan BERNARD a Vlastimil VÁLEK. Endoluminal radiofrequency ablation of hilarcholangiocarcinoma. In \textit{ESGAR 2016}. 2016. Dostupné z: https://doi.org/10.1007/s13244-016-0502-9.

Přehled o publikaci